436 results about "Ornithine" patented technology

Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)

The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and / or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and / or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.

In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin salt. In another aspect, the present invention provides methods for treating or preventing cancer using the conjugates or salts of eflornithine analogs or eflornithine prodrugs.

The invention provides a method of synthesizing a diketopiperazine of the formula: wherein:R1 is —CH2COR3, or —CH2CH2COR3;R2 is the side chain of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, phenylalanine, tyrosine, tryptophan, thyroxine, cysteine, methionine, norvaline and ornithine;R3 is —OH, —NH2, —OR4, —NHR4, or —NR4R4; andeach R4 is independently an alkyl, aryl, alkylaryl, or arylalkyl.

Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, an ECM protein, or a biologically active fragment or variant thereof such as elastin, fibronectin, vitronectin, laminin, collagen I, collagen III, collagen IV, and collagen VI. Also, optionally present on the surface is an active factor, preferably a polycationic polymer or a biologically active fragment or variant thereof, such as polyethyleneimine (PEI), poly-D-lysine (PDL), poly-L-lysine (PLL), poly-D-ornithine (PDO) or poly-L-ornithine (PLO). This surface is used in cell culture to promote cell attachment, survival, and / or proliferation of primary liver cells. The invention also relates to methods utilizing this surface, such as methods for attachment, survival, and / or proliferation of cells. Further disclosed is the use of the surface in cell culture with serum-free medium. Methods of screening using the surface of the invention are also disclosed.

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and / or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

A compound preparation consists of ornithine or its salt and asparagic acid or its salt as well as proper amount of supplementary material; and is prepared into oral preparation or injection through mechanical mixing and other process. The said compound preparation is used for treating various acute hepatitis, chronic hepatosis and hepatic encephacopathy and has the obvious effects of protecting liver and strengthening physique. The preparation process is simple, short in production period and low in cost.

Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and / or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

The invention features methods and compositions for diagnosis and treatment of conditions associated with decreased nitric oxide bioavailability, such as a condition associated with elevated arginase activity, using an arginine- and / or arginase-inhibitor based therapy, which therapies include administration of arginine or an arginase inhibitor, either alone or in combination. The invention also contemplates administration of magnesium with arginine, an arginase inhibitor, or with arginine-arginase inhibitor combination therapy. The invention also features methods and compositions for diagnosis, including prognosis, of conditions associated with arginase activity by assessing the ratio of arginine to ornithine in samples from a subject.

The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.

The present invention relates to the treatment of wounds by the topical administration of arginine or ornithine to wound sites. There is described herein a wound healing enhancing medicinal composition formulated from the amino acid arginine or a by-product thereof. Topical application of the medicinal composition to the wound site enhances wound healing by increasing collagen biosynthesis. A medical composition of the present invention may be administered alone, on dressings, or in combination with common vehicles for topical application including, for example, oil-based emulsions, gels, creams, ointments, and the like.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

A composition is described, which comprises a cationic, hydrophilic, amine containing polymer, chosen from the group consisting of native chitosan and cationic derivatives thereof; cationic polyethylene compounds; DEAE-4; or polyornitine; bound to an anionic scavenger substance, which is (a) either chosen from the group consisting of anionic ethylene amine compounds, tetraazacykloalkane-N,N,N,N-tetraacetic acids; and polymer derivatives of porphyrines, or (b) is an endogenous compound.

The invention discloses a preparing method of bifidobacteria bacterial active agent and single-purpose protecting agent, which is characterized by the following: allocating 0.01-5.0 wt glycerin, 0.1-6.0 wt polyvinyl pyrrolidon, 0.1-5.0 carbowax, 1.0-10.0 wt skimmed milk powder, 0.5-15.0 wt mycose, 0.1-5.0 wt glutavene, 0.1-5.0 wt L-aspartic acid, 0.1-5.0 wt vitamin C sodium and 0.1-5.0 wt ornithine hydrochlorate. This invention solves the problem of preservation difficulty at normal temperature with conventional method.

The present invention provides a soybean peptide beverage whose composition includes (by weight portion ratio) cane sugar 36000-14000000, oligo maltose 24000-9600000, soybean oligopeptide 19000-760000, ornithine 400-19000 and creatine 2000-100000. Besides, said invention also provides health-care functions of said soybean peptide beverage.

The invention belongs to the field of biological pharmaceutics, and discloses a method for separating and purifying L-ornithine by using a simulated moving bed. The method comprises the following steps: firstly, removing bacteria and solid substances from L-ornithine fermentation solution by using ultra-filtration; secondly, feeding the solution into the simulated moving bed, adsorbing the solution, washing the impurities, eluting the L-ornithine, collecting the elution and regenerating a column; and finally, concentrating and decolorizing the collected elution, adjusting the pH of the elution to between 4.5 and 5.0 with hydrochloric acid, crystallizing the elution, and drying the crystal to obtain L-ornithine hydrochloride crystal. The L-ornithine separated and purified by using the method has the advantages of high yield, high purity, low cost, environmental protection, and suitability for industrialized production.

The invention belongs to the field of fermentation engineering and discloses corynebacterium glutamicum and a method for preparing L-ornithine and salts thereof by using the same. The corynebacterium glutamicum is corynebacterium glutamicum 1006 with the collection number of CGMCCNo.3663. The method comprises the following steps of: culturing the corynebacterium glutamicum in a culture medium containing carbon sources, nitrogen sources and inorganic salts at the temperature of between 28 and 30 DEG C to generate L-ornithine fermentation liquor; removing the thalli of the fermentation liquor by using ceramic membranes of 1 to 15 ten thousand Dalton; separating the fermentation liquor by using cation exchange resins to obtain L-ornithine solution; and decoloring and crystallizing the L-ornithine solution by a hydrochloric acid and ethanol method to obtain L-ornithine hydrochloride. The method has the advantages of simple thallus cultivation and contribution to industrialized mass production. The accumulation of the L-ornithine prepared from the corynebacterium glutamicum reaches 35 to 45g / L.

Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.

The invention provides a preparation method of ornithine aspartate, which comprises the following steps: firstly dissolving ornithine salt in water, adjusting the pH to 8-11 with alkali liquor, obtaining free ornithine by an electrodialysis method, adjusting the pH of the solution to 7-9 with aspartic acid, performing concentration, and adding an alcoholic solution for crystallization. The method of the invention can realize desalting effect, needs no spherical or powdery ion exchange resin materials or column chromatography filling materials, is simple in production process, high in production efficiency, low in cost, more stable in materials during production process, high in product yield, high in purity, less in production waste liquid, and beneficial to environmental protection.

A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided.According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a salt thereof as active ingredients can be provided.

Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.

The invention belongs to a yellow wine brewing method, which comprises the steps of rice soaking, rice steaming, water spraying, jar falling and pot erecting, yeast and water addition, fermentation and post treatment, wherein L-ornithine monohydrochloride is added into fermentation liquid in the second day to the six day after the jar falling and pot erecting. The yellow wine brewing method has the advantages that the L-ornithine monohydrochloride as an inhibitor is easy to control, the inhibition efficiency is high, and the generation of ethyl carbamate can be effectively inhibited; after the L-ornithine monohydrochloride is dissolved in water, ornithine is generated and participates in uric acid circulation in vivo, no risk and no toxic and harm exist, and no environment pollution is caused; and in addition, the L-ornithine monohydrochloride is easy to obtain, the use is convenient, and the cost is low.